Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide once weekly versus insulin glargine in insulin-naive adults with type 2 diabetes
NL-OMON41148Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide and insulin glargine in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline to week 30 in HbA1c. Started Sep 2014; status: active, not recruiting.
02
Drugs
semaglutideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON41148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41148.